Adam’s Take
Insights and opinions from senior biotech writer Adam Feuerstein.
Recent topics include Apellis Pharmaceuticals, Moonlake Immunotherapeutics, PDS Biotech, Rubius Therapeutics, Amylyx Pharmaceuticals and Anavex Life Sciences.
Latest
STAT Plus: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind
STAT Plus: What’s behind the recent surge in Apellis’ stock price? Growing confidence in the safety of its eye treatment
STAT Plus: Anavex, maker of rare disease drug, keeps shifting the goalposts in its clinical trials
STAT Plus: A conflict of interest behind the warning on Apellis’ eye drug? The optics are not good
STAT Plus: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain
STAT Plus: Instead of credible data, PDS Biotech delivers ‘results might get better, later’ promises
STAT Plus: Annexon’s trial of an eye disease drug missed by a mile. The company saw a bull’s eye
All Coverage
advertisement
